amonafide has been researched along with Melanoma in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (25.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 3 (75.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Cheng, CC; Zee-Cheng, RK | 1 |
Chang, CM; Chang, KS; Chen, TL; Hsiao, CA; Liu, JW; Lu, YT; Shih, TL; Wei, TY | 1 |
Ben-David, G; Firer, MA; Gancz, A; Gellerman, G; Gilad, Y; Luboshits, G; Minnes, R; Senderowitz, H; Tuchinsky, H | 1 |
Kampert, TL; Misra, SK; Pan, D | 1 |
4 other study(ies) available for amonafide and Melanoma
Article | Year |
---|---|
N-(Aminoalkyl)imide antineoplastic agents. Synthesis and biological activity.
Topics: Adenocarcinoma; Animals; Chemical Phenomena; Chemistry; Colonic Neoplasms; Humans; Imides; Leukemia L1210; Leukemia P388; Melanoma; Neoplasms; Structure-Activity Relationship | 1985 |
Synthesis of novel C4-benzazole naphthalimide derivatives with potent anti-tumor properties against murine melanoma.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Melanoma; Mice; Mice, Inbred C57BL; Molecular Structure; Naphthalimides; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2017 |
Discovery of potent molecular chimera (CM358) to treat human metastatic melanoma.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Heterocyclic Compounds, 3-Ring; Humans; Melanoma; Mice; Mice, Nude; Models, Molecular; Molecular Structure; Neoplasms, Experimental; Pyrimidinones; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2017 |
Nano-Assembly of Pamitoyl-Bioconjugated Coenzyme-A for Combinatorial Chemo-Biologics in Transcriptional Therapy.
Topics: Adenine; Antineoplastic Agents; Cell Line, Tumor; Coenzyme A; Drug Carriers; Humans; Melanoma; Nanoparticles; Naphthalimides; Organophosphonates; Protein Multimerization; Proto-Oncogene Proteins c-myc; RNA, Small Interfering; RNAi Therapeutics | 2018 |